Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch
09 mars 2022 07h30 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, March 09, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering
08 mars 2022 11h45 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, March 08, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat...
Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer
02 mars 2022 07h00 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma
28 févr. 2022 09h12 HE
|
Akari Therapeutics Plc
Akari’s complement and leukotriene inhibitor, nomacopan, demonstrated improved survival (80% vs. 30%) in a preclinical model of traumaA follow-on program relevant to both military and civilian trauma...
Akari Therapeutics to Present at BIO CEO & Investor Conference
11 févr. 2022 07h00 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases
26 janv. 2022 08h30 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies
19 janv. 2022 08h30 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
04 janv. 2022 07h00 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering
30 déc. 2021 11h03 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat...
Akari Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Clinical Progress
03 déc. 2021 07h45 HE
|
Akari Therapeutics Plc
Sites opened in Phase III study of nomacopan in bullous pemphigoid (BP)Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA)...